Oncocross to co-develop 'dual-target siRNA' with Curi-Jin and Omics AI
Predicted impact: Low
Co-development agreement for a dual-target siRNA; no deal value or revenue share disclosed.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.